X4 PHARMACEUTICALS INC (XFOR)
Health Care · Orphan drug / rare disease immunology · NASDAQ
X4 Pharmaceuticals develops CXCR4 antagonist therapies, with its FDA-approved product XOLREMDI for rare neutrophil-mobilization disorders.
What X4 PHARMACEUTICALS INC does
X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. The company's lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the FDA to increase the number of circulating mature neutrophils and lymphocytes in patients 12 years and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. X4 is currently focused on generating revenue from XOLREMDI sales and developing additional product candidates in related areas.
Themes: ["rare disease / orphan drug"]
Fundamentals
- Price$3.96 as of 2026-07-09 close
- Market cap$353M as of 2026-07-10
- 1-year return+138.6% as of 2026-07-09 close
- Net margin-1106.3% as of 2026-07-10
- Gross margin+81.8% as of 2026-07-10
- ROE-94.9% as of 2026-07-10
- Debt / equity0.45 as of 2026-07-10
- Revenue growth (YoY)-71.3% as of 2026-07-10
- Beta0.38 as of 2026-07-10
Key risks (from latest filing)
["Dependence on a single approved product (XOLREMDI) with unknown market size and growth potential; company has not yet generated significant revenue from product sales and may never achieve profitability"]
Competitors & peers
- Novartis (NVS) — broad rare disease and immunology portfolio
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.